Frank Buchholz, Professor for Medical Systems Biology at the TU Dresden Faculty of Medicine Carl Gustav Carus was awarded an ERC Advanced Grant worth EUR 2.4 million for his research in the field of targeted genome surgery based on evolved site-specific recombinases. The team headed by Prof. Buchholz already succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates found in humans. Now Frank Buchholz’ research is also focusing on various other diseases. “The generation of molecular scalpels, such as the Brec1 recombinase, will change medical practice. Not only HIV patients will likely benefit from this development, but presumably also many other patients. We are about to witness the beginning of the genome surgery era”, predicts the head of the Dresden research group, Prof. Frank Buchholz. In the funded “GenSurge” project, a “genome-editing platform” will be developed which allows efficient and safe DNA modifications without triggering cell intrinsic DNA repair.

Comments are closed.